The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 19, 2019
Filed:
Mar. 24, 2016
Applicant:
Astex Therapeutics Ltd, Cambridge, GB;
Inventors:
Jayaprakash Karkera, Germantown, MD (US);
Suso Jesus Platero, Washington Crossing, PA (US);
Raluca Verona, Swarthmore, PA (US);
Matthew V. Lorenzi, Philadelphia, PA (US);
Assignee:
ASTEX THERAPEUTICS LTD, Cambridge, GB;
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); C07K 16/28 (2006.01); A61K 31/498 (2006.01); A61K 39/395 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/498 (2013.01); A61K 45/06 (2013.01); C07K 16/2818 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57492 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/52 (2013.01);
Abstract
Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.